Advancing translational medicine to cure Rett Syndrome and MECP2 duplication through programs in gene therapy, protein replacement, X reactivation, and RNA editing. Directs clinical initiatives in outcome measures and biomarker identification. Leads FDA-regulated and non-regulated studies to improve the lives of individuals with Rett Syndrome. Identifies promising technologies and recruits new investigators. Has previously managed clinical development planning, protocol design, trial execution and data analysis in industry. Experience in oncology, CNS, dermatology, and rare disorders. Proficient in vendor management, trial management, scientific writing and presentation. Management style is goal-oriented, collaborative, transparent and proactive. Values efficiency, communication and results.